Trial document
DRKS00006851
Trial Description
Title
Correlation of subjective visual parameters with morphologic parameters in reactivation of exsudative maculopathies
Trial Acronym
[---]*
URL of the Trial
[---]*
Brief Summary in Lay Language
[---]*
Brief Summary in Scientific Language
Different exsudative diseases of the macula (e.g. age related maculopathy (AMD), diabetic macular edema (DME), macular edema in retinal vein occlusion (RVO), myopic choroidal neovascularisation (CNV)) are currently treated by intravitreal injection of VEGF inhibitors. The official recommendations of the german ophthalmological associations (DOG, BVA, RG) include that affected patients shall be controlled in monthly intervals after the end of treatment. These controls require a high logistic support for both patients and examiner (time, transport, devices). The aim of this study is to investigate wether subjective parameters (estimation of the visual acuity and the metamorphopsia) can help to detect reliably a reactivation of disease. For this purpose we plan to compare the current gold standard of clinical examination (visual acuity, morphologic examination with the optical coherence tomography (OCT)) with the above-named subjective parameters. We try to identify patient groups in which the control interval might be adapted. Different diseases (AMD, DME, RVO, myopic CNV) shall be analyzed. In a second step the correlation between subjecitve parameters and morphologic parameters shall be investigated.
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00006851
- 2014/10/09
- [---]*
- yes
- Approved
- 413/14, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
Secondary IDs
- [---]*
Health Condition or Problem studied
- H35.3 - Degeneration of macula and posterior pole
Interventions/Observational Groups
-
non-interventional study
retrospective data analysis of all patients who were examined in the clinical "IVOM-OCT-consultation" (clinical control of the success of treatment about 8 weeks after the last intravitreal injection, 4 weeks after the first control of success). If several appointments in the "IVOM-OCT-consultation" have taken place only the first documented appointment will be analysed (analysis of the documented subjective
estimation of visual acuity and metamorphopsia, analysis of the documented visual acuity, analysis of the executed OCT)
Characteristics
- Non-interventional
- Other
- Single arm study
- Open (masking not used)
- [---]*
- Uncontrolled/Single arm
- Diagnostic
- Single (group)
- N/A
- N/A
Primary Outcome
specificity and sensitivity of subjective parameter (e.g. visual acuity, metamorphopsia; evaluation of the subjective devolopment as defined by better / worse / equal) in the evaluation of activity of maculopathy in age related maculopathy, retinal vein occlusion, diabetic retinopathy and other maculopathies
Secondary Outcome
Differences in specificity and sensitivity of the above-named parameter in different diseases, identification of characteristics of the morphology in reactivated disease, correlation of these characteristics with subjective parameter, correlation with basic data (eye function, age)
Countries of Recruitment
- Germany
Locations of Recruitment
- University Medical Center
Recruitment
- Planned
- 2014/10/15
- 1200
- Monocenter trial
- National
Inclusion Criteria
- Both, male and female
- 18 Years
- no maximum age
Additional Inclusion Criteria
first examination of patients with maculopathy (age related maculopathy, diabetes, retinal vein occlusion, myopia, other diseases with development of choroidal neovascularisation) having received intravitreal injections with anti-VEGF (bevacizumab, ranibizumab, aflibercept) who were adjudged to be not in need of further treatment and were appointed to control examinations in the "IVOM-OCT-Sprechstunde"
Exclusion Criteria
examination other than primary examination, other interventions (e.g. injection of TAC, Jetrea, Ozurdex), surgery of the study eye in the intervall between last intravitreal injection and OCT control
Addresses
-
start of 1:1-Block address primary-sponsor
- Klinik für AugenheilkundeUniversitätsklinikum Freiburg
- Killianstr. 5
- 79106 Freiburg
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address other
- Klinik für AugenheilkundeUniversitätsklinikum Freiburg
- Mr. Dr. Christoph Ehlken
- Killianstr. 5
- 79106 Freiburg
- Germany
end of 1:1-Block address otherstart of 1:1-Block address contact other- 0761/270-40010
- [---]*
- christoph.ehlken at uniklinik-freiburg.de
- [---]*
end of 1:1-Block address contact other -
start of 1:1-Block address scientific-contact
- Klinik für AugenheilkundeUniversitätsklinikum Freiburg
- Mr. Dr. Christoph Ehlken
- Killianstr. 5
- 79106 Freiburg
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 0761/270-40010
- [---]*
- christoph.ehlken at uniklinik-freiburg.de
- [---]*
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Klinik für AugenheilkundeUniversitätsklinikum Freiburg
- Mr. Dr. Christoph Ehlken
- Killianstr. 5
- 79106 Freiburg
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 0761/270-40010
- [---]*
- christoph.ehlken at uniklinik-freiburg.de
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Klinik für AugenheilkundeUniversitätsklinikum Freiburg
- Killianstr. 5
- 79106 Freiburg
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact materialSupport
Status
- Recruiting planned
- [---]*
Trial Publications, Results and other Documents
- [---]*